PubMed

Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma.

Savas B, Kerr PE, Pross HF.

Cancer Cell Int. 2006 Nov 3;6:24.PMID: 17081316 [PubMed]Related articlesFree article

P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.

Savas B, Cole SP, Tsuruo T, Pross HF.

J Clin Immunol. 1996 Nov;16(6):348-57.PMID: 8946280 [PubMed - indexed for MEDLINE]Related articles

Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.

Scheper RJ, Dalton WS, Grogan TM, Schlosser A, Bellamy WT, Taylor CW, Scuderi P, Spier C.

Int J Cancer. 1991 Jun 19;48(4):562-7.PMID: 1710609 [PubMed - indexed for MEDLINE]Related articles

Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants.

Gross N, Favre S, Beck D, Meyer M.

Int J Cancer. 1992 Aug 19;52(1):85-91.PMID: 1354203 [PubMed - indexed for MEDLINE]Related articles

Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.

Grant AJ, Merchant RE, Hall RE.

Immunology. 1989 Jan;66(1):117-24.PMID: 15493273 [PubMed - indexed for MEDLINE]Related articlesFree article

Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.

Savas B, Kerr PE, Ustun H, Cole SP, Pross HF.

Anticancer Res. 1998 Nov-Dec;18(6A):4355-61.PMID: 9891492 [PubMed - indexed for MEDLINE]Related articles

Role of enhanced cellular adhesion in IL-6-augmented lymphokine-activated killer-cell function.

Iho S, Shau H.

Scand J Immunol. 1994 Mar;39(3):233-40.PMID: 8128185 [PubMed - indexed for MEDLINE]Related articles

5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle.

Tomita Y, Imai T, Katagiri A, Kimura M, Saitoh K, Sato S.

Cancer Lett. 1993 Nov 30;75(1):27-34.PMID: 7904537 [PubMed - indexed for MEDLINE]Related articles

Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.

Fady C, Gardner A, Gera JF, Lichtenstein A.

Cancer Immunol Immunother. 1993 May;36(5):307-14.PMID: 8097427 [PubMed - indexed for MEDLINE]Related articles

Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity.

Thomas X, Anglaret B, Adeleine P, Maritaz O, Bailly M, Fiere D, Archimbaud E.

Leuk Lymphoma. 1998 Jan;28(3-4):343-53.PMID: 9517505 [PubMed - indexed for MEDLINE]Related articles

Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.

Treichel RS, Bunuan M, Hahn N, Wee K.

Int J Cancer. 2004 Jan 1;108(1):78-85.PMID: 14618619 [PubMed - indexed for MEDLINE]Related articles

Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines.

Hirose M, Hamano S, Tobinai K, Kuroda Y.

J Immunother. 1999 May;22(3):237-44.PMID: 10335483 [PubMed - indexed for MEDLINE]Related articles

Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.

Ozkan A, Ayhan A, Fiskin K.

Cell Biol Toxicol. 2004 Sep;20(5):261-71.PMID: 15685929 [PubMed - indexed for MEDLINE]Related articles

[Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells]

Zheng YJ, Zhang J, Wang SM, Zhang JR.

Di Yi Jun Yi Da Xue Xue Bao. 2004 Apr;24(4):392-6. Chinese. PMID: 15090306 [PubMed - indexed for MEDLINE]Related articles

CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.

Komatsu F, Kajiwara M.

Oncol Res. 2000;12(1):17-24.PMID: 11061342 [PubMed - indexed for MEDLINE]Related articles

A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.

Komatsu F, Kajiwara M.

Oncol Res. 1998;10(5):263-9.PMID: 9802061 [PubMed - indexed for MEDLINE]Related articles

Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors.

Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, Carson WE 3rd.

J Surg Res. 2007 May 1;139(1):36-44. Epub 2007 Feb 9.PMID: 17292412 [PubMed - indexed for MEDLINE]Related articlesFree article

Cytokine modulation of the susceptibility of acute T-lymphoblastic leukemia cell lines to LAK activity.

Cesano A, Clark SC, Santoli D.

Leukemia. 1993 Mar;7(3):404-9.PMID: 8445946 [PubMed - indexed for MEDLINE]Related articles

[Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]

Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.

Ai Zheng. 2007 Aug;26(8):837-42. Chinese. PMID: 17697543 [PubMed - indexed for MEDLINE]Related articlesFree article

Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and expression of adhesion molecules in B-cell derived non-Hodgkin's lymphomas.

Chaperot L, Jacob MC, Le Vacon F, Giroux C, Molens JP, Sotto JJ, Bensa JC, Plumas J.

Leuk Lymphoma. 1997 Dec;28(1-2):133-43.PMID: 9498712 [PubMed - indexed for MEDLINE]Related articles